Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma.
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma.
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
Treatment of malignant mesothelioma.
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases.
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
Mesothelioma and radical multimodality therapy: who benefits?
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
Malignant pleural mesothelioma: overview of the North American and European experience.
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.